14100-97-1

Basic information

• Product Name: CYCLOHEXANEMETHANOL, 1-METHANSULFONATE
• Synonyms: CYCLOHEXANEMETHANOL, 1-METHANSULFONATE;Cyclohexylmethyl mesylate;Cyclohexylmethyl methanesulphonate
• CAS NO: 14100-97-1
• Molecular Formula: C₈H₁₆O₃S
• Molecular Weight: 208.276
• Mol File: 14100-97-1.mol

Chemical Properties

• Boiling Point: 316.9±11.0 °C(Predicted)
• Appearance: /
• Density: 1.121±0.06 g/cm3(Predicted)
• CAS DataBase Reference: CYCLOHEXANEMETHANOL, 1-METHANSULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOHEXANEMETHANOL, 1-METHANSULFONATE(14100-97-1)
• EPA Substance Registry System: CYCLOHEXANEMETHANOL, 1-METHANSULFONATE(14100-97-1)

Safety Data

• Hazardous Substances Data: 14100-97-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CYCLOHEXANEMETHANOL, 1-METHANSULFONATE is used as a reactant for the preparation of (adamantanylureido)cyclohexanol derivatives, which are potent soluble epoxide hydrolase inhibitors. These derivatives have potential applications in the development of orally bioavailable drugs for treating various medical conditions.
Used in Chemical Synthesis:
CYCLOHEXANEMETHANOL, 1-METHANSULFONATE is used as an intermediate in the synthesis of various chemical compounds due to its reactive nature. Its unique structure allows it to participate in a range of chemical reactions, making it a valuable component in the creation of new molecules with specific properties and applications.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 100-49-2 cyclohexylmethyl alcohol 

Downstream Products

• 36293-56-8 (cyclohexylmethyl)(phenyl)sulfide 
• 5469-33-0 cyclohexylmethyl iodide 
• 919092-54-9 4-cyclohexylmethoxy-2-hydroxyacetophenone 
• 919092-53-8 1-(2-(cyclohexylmethoxy)-6-hydroxyphenyl)ethanone 
• 935548-19-9 3-(4-cyclohexylmethoxy-phenyl)-2-hexadecanoylamino-propionic acid methyl ester 
• 935548-20-2 3-(4-cyclohexylmethoxy-phenyl)-2-hexadecanoylamino-propionic acid methyl ester 
• 935548-37-1 [4-(4-cyclohexylmethoxy-phenyl)-3-hexadecanoylamino-2-oxo-butyl]-phosphonic acid dimethyl ester 
• 935548-38-2 [4-(4-cyclohexylmethoxy-phenyl)-3-hexadecanoylamino-2-oxo-butyl]-phosphonic acid dimethyl ester 
• 935548-61-1 [4-(4-cyclohexylmethoxy-phenyl)-3-hexadecanoylamino-2-hydroxy-butyl]-phosphonic acid dimethyl ester 
• 935548-62-2 [4-(4-cyclohexylmethoxy-phenyl)-3-hexadecanoylamino-2-hydroxy-butyl]-phosphonic acid dimethyl ester 
• 956627-18-2 (E)-1-(4-Cyclohexylmethoxy-2-hydroxy-phenyl)-3-(4-methoxymethoxy-phenyl)-propenone 

Relevant articles and documents

Convenient Continuous Flow Synthesis of N-Methyl Secondary Amines from Alkyl Mesylates and Epoxides

The first continuous flow process was developed to synthesize N-methyl secondary amines from alkyl mesylates and epoxides via a nucleophilic substitution using aqueous methylamine. A variety of N-methyl secondary amines were produced in good to excellent yields, including a number of bioactive compounds or their precursors. Up to 10.6 g (88% yield) of an N-methyl secondary amine was produced in 140 min process time. The amination procedure included an in-line workup, and the starting mesylate material was also produced in continuous flow from the corresponding alcohol. Finally, an in-line process combining the mesylate synthesis and nucleophilic substitution was developed.

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors

The multiple roles of protein kinase D (PKD) in various cancer hallmarks have been repeatedly reported. Therefore, the search for novel PKD inhibitors and their evaluation as antitumor agents has gained considerable attention. In this work, novel pyrazolo[3,4-d]pyrimidine based pan-PKD inhibitors with structural variety at position 1 were synthesized and evaluated for biological activity. Starting from 3-IN-PP1, a known PKD inhibitor with IC50 values in the range of 94–108 nM, compound 17m was identified with an improved biochemical inhibitory activity against PKD (IC50 = 17–35 nM). Subsequent cellular assays demonstrated that 3-IN-PP1 and 17m inhibited PKD-dependent cortactin phosphorylation. Furthermore, 3-IN-PP1 displayed potent anti-proliferative activity against PANC-1 cells. Finally, a screening against different cancer cell lines demonstrated that 3-IN-PP1 is a potent and versatile antitumoral agent.

MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

MITOCHONDRIA-TARGETING PEPTIDES

Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

One-pot preparation of Julia-Kocienski sulfides and sulfones from alcohols

A method for one-pot preparation of Julia-Kocienski sulfides and sulfones from alcohols and thiols is reported. A variety of primary alcohols were converted to the corresponding mesylates by methansulfonyl chloride and triethylamine in THF. After the reaction is complete, thiol (1 or 10) and either NaH or t-BuOK were added. The Julia-Kocienski sulfides 3, 9 and 11 were prepared by one-pot two steps procedure from alcohols in 76–96% yields (16 examples). Furthermore, after the sulfide formation, the reaction mixture was neutralized by p-toluenesulfonic acid and treated with H2O2 and ammonium molybdate in EtOH to give the Julia-Kocienski sulfones 4 in good yields except for trans-2-hexen-1-ol.

1,2,3-Triazolium-Based Cationic Amphipathic Peptoid Oligomers Mimicking Antimicrobial Helical Peptides

Amphipathic cationic peptoids (N-substituted glycine oligomers) represent a promising class of antimicrobial peptide mimics. The aim of this study is to explore the potential of the triazolium group as a cationic moiety and helix inducer to develop potent antimicrobial helical peptoids. Herein we report the first solid-phase synthesis of peptoid oligomers incorporating 1,2,3-triazolium-type side chains and their evaluation against Escherichia coli, Enterococcus faecalis, and Staphylococcus aureus. Several triazolium-based oligomers, even of short length, selectively kill bacteria over mammalian cells. SEM visualization of S. aureus cells treated with a dodecamer and a hexamer reveals severe cell membrane damage and suggests that the longer oligomer acts by pore formation.

ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS

The present invention relates to arylcyclohexyl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Method for synthesizing azanol

The invention relates to a hydroxylamine synthesis method. The hydroxylamine synthesis method comprises the following steps: (A) enabling alcohol to react with alkyl sulfonyl halide in the presence of an acid-binding agent to obtain sulphonate; (B) enabling the obtained sulphonate in the step (A) to react with N-hydroxycyclodiimide in the presence of alkali to generate alkylate of the N-hydroxycyclodiimide; and (C) enabling the alkylate obtained in the step (B) to react with an aminolysis reagent or a hydrazinolysis reagent to obtain the hydroxylamine. The method is high in yield and suitable for large-scale industrial hydroxylamine synthesis.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Heterocyclic substituted aniline calcium channel blockers

The present invention provides compounds that block calcium channels having the Formula I shown below. STR1The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, epilepsy, asthma, amyotrophic lateral sclerosis, or pain and to pharmaceutical compositions that contain the compounds of Formula I.